A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML

NCT02896842 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

139

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

DRUG: Posology dose modification
OTHER: active comparator

Sponsor

Versailles Hospital